News brief­ing: Glax­o­SmithK­line adds to flur­ry of deal­mak­ing; Take­da strikes $322M deal to of­fload a non-core port­fo­lio

As 2020 winds down, British drug­mak­er Glax­o­SmithK­line con­tin­ues a flur­ry of biotech deal­mak­ing — this time fo­cused on small mol­e­cule ther­a­peu­tics that tar­get trans­mem­brane …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER